Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.
Cellanome engages in cutting-edge synthetic biology and informatics methods through its multi-omics platform.
Discovery Tools (Healthcare)📍 Foster City, CAFounded 2020
Current Valuation
$525M
as of 2024-Q1
PRIVATE
QL Price
$525M
0% vs last round
QuantLogix's current estimate for Cellanome, published 2026-09-27 — in line with the last disclosed round of $525M (2024-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$525M
2024-Q1
weight 0.18
How this price has held up
No round has priced for Cellanome since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Cellanome, 2026-09-27 (1393de1e279d8877).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Cellanome going public?
No. Cellanome is private and has not filed to go public. There is no S-1 on file.
What is Cellanome's valuation in 2026?
Cellanome is valued at $525M as of 2024-Q1, set by its Series B ($150M, Jan 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Cellanome filed an S-1?
No public S-1 is on file for Cellanome.
How much has Cellanome raised?
Cellanome has raised $216.31M in total, most recently a Series B of $150M in Jan 2024.
Is Cellanome publicly traded — can you buy Cellanome stock?
No. Cellanome is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Cellanome on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2020
HQ
Foster City, CA
Employees
127
Total Raised
$216.31M
Last Round
Series B — $150M (Jan 2024)
IPO Status
private
Fundraising Status
Series B · $150M · 2y 8mo ago
privateTotal raised $216.31M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$150M
Jan 2024
—
$525M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Cellanome — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+63% vs 2026-08
Open roles
13
via greenhouse
Product-build share
69%
engineering, research, product, design
Trajectory
expanding
heavy product build — 69% of open roles are product-building functions (engineering/research/product) — 3 of 13 open roles are engineering.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Head of Systems EngineeringLead Research Associate, ServicesMachine Learning EngineerResearch Associate II (Temporary)Senior Field Service EngineerSenior Staff Manufacturing Process Engineer
Counted from Cellanome's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyGeneticsLife Science
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q1. Refreshed quarterly.